IHE
iShares U.S. Pharmaceuticals ETF
iShares Trust
ETFIndex fund
Expense ratio1
0.38%
Net assets2
$1.00B
Holdings2
58
Category
US Equity
2025 return3
31.74%

Investment objective & strategy

As of July 22, 2025 · prospectus

Objective. The iShares U.S. Pharmaceuticals ETF (the Fund ) seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector.

Strategy. The Fund seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index (the Underlying Index ), which measures the performance of the pharmaceuticals sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC (the Index Provider or SPDJI ). The Underlying Index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The Underlying Index may include large-, mid- or small-capitalization companies. As of March 31, 2025, a significant portion of the Underlying Index is represented by securities of companies in the healthcare and pharmaceuticals industries or sectors. The components of the Underlying Index are likely to change over time. BFA uses an indexing approach to try to achieve … The Fund seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index (the Underlying Index ), which measures the performance of the pharmaceuticals sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC (the Index Provider or SPDJI ). The Underlying Index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The Underlying Index may include large-, mid- or small-capitalization companies. As of March 31, 2025, a significant portion of the Underlying Index is represented by securities of companies in the healthcare and pharmaceuticals industries or sectors. The components of the Underlying Index are likely to change over time. BFA uses an indexing approach to try to achieve the Funds investment objective. The Fund does not try to beat the index it tracks and does not seek temporary defensive positions when markets decline or appear overvalued. Indexing may eliminate the chance that the Fund will substantially outperform the Underlying Index but also may reduce some of the risks of active management, such as poor security selection. Indexing seeks to achieve lower costs and better after-tax performance by aiming to keep portfolio turnover low in comparison to actively managed investment companies. BFA uses a representative sampling indexing strategy to manage the Fund. Representative sampling is an indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to that of an applicable underlying index. The securities selected are expected to have, in the aggregate, investment characteristics (based on factors such as market capitalization and industry weightings), fundamental characteristics (such as return variability and yield) and liquidity measures similar to those of an applicable underlying index. The Fund may or may not hold all of the securities in the Underlying Index. The Fund generally will invest at least 80% of its assets in the component securities of its Underlying Index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, including shares of money market funds advised by BFA or its affiliates, as well as in securities not included in the Underlying Index, but which BFA believes will help the Fund track the Underlying Index. Cash and cash equivalent investments associated with a derivative position will be treated as part of that position for the purposes of calculating the percentage of investments included in the Underlying Index. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund. The Fund may lend securities representing up to one-third of the value of the Fund's total assets (including the value of any collateral received). The Underlying Index is sponsored by SPDJI, which is ? independent of the Fund and BFA. The Index Provider determines the composition and relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index. Industry Concentration Policy. The Fund will concentrate its investments ( i.e. , hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. For purposes of this limitation, securities of the U.S. government (including its agencies and instrumentalities) and repurchase agreements collateralized by U.S. government securities are not considered to be issued by members of any industry.

Top holdings

As of March 31, 2026 · N-PORT
SecurityTickerValue% of fund
JOHNSON&JOHNSON $230.42M 23.03%
LILLY ELI and CO $210.71M 21.06%
MERCK & CO $47.42M 4.74%
PFIZER INC $47.12M 4.71%
ROYALTY PHARMA-A $47.07M 4.70%
BRISTOL-MYERS SQUIBB CO $46.32M 4.63%
ZOETIS INC CL A $45.21M 4.52%
BlackRock Cash Funds: Institutional, SL Agency Shares BISXX $43.58M 4.36%
VIATRIS INC $43.49M 4.35%
ELANCO ANIMAL HEALTH INC $33.23M 3.32%
View all holdings →

Allocation by sector

As of March 31, 2026 · N-PORT
View portfolio breakdown →

Portfolio moves

Dec 31, 2025 → Mar 31, 2026
Opened
6
Exited
5
Increased
53
Decreased
0
Unchanged
0

How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.

View portfolio moves →

Similar funds

Funds whose portfolios most overlap this one, by weight

Advisers

As of March 31, 2025 · N-CEN
FirmRole
BlackRock Fund Advisors Adviser

Footnotes

  1. Expense ratio as of July 22, 2025, from the fund's prospectus.
  2. Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
  3. Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).

Machine-readable: JSON · Markdown. Programmatic access via the agent surface.